J Haensler

Summary

Affiliation: Sanofi Pasteur

Publications

  1. ncbi request reprint Manufacture of Oil-in-Water Emulsion Adjuvants
    Jean Haensler
    Sanofi Pasteur R and D, Campus Merieux, 1541 Avenue Marcel Merieux, 69280, Marcy l Etoile, France
    Methods Mol Biol 1494:165-180. 2017
  2. doi request reprint Design and preclinical characterization of a novel vaccine adjuvant formulation consisting of a synthetic TLR4 agonist in a thermoreversible squalene emulsion
    Jean Haensler
    Sanofi Pasteur R and D, Marcy l Etoile, France Electronic address
    Int J Pharm 486:99-111. 2015
  3. doi request reprint [Introduction to novel vaccine adjuvants and their role in influenza vaccination]
    J Haensler
    Discovery R and D, Sanofi Pasteur, Campus Merieux, 1541, avenue Marcel Mérieux, 69280 Marcy l Etoile, France
    Ann Pharm Fr 71:104-8. 2013

Detail Information

Publications3

  1. ncbi request reprint Manufacture of Oil-in-Water Emulsion Adjuvants
    Jean Haensler
    Sanofi Pasteur R and D, Campus Merieux, 1541 Avenue Marcel Merieux, 69280, Marcy l Etoile, France
    Methods Mol Biol 1494:165-180. 2017
    ..Two manufacturing processes, high pressure homogenization (HPH or microfluidization) and a phase inversion temperature method (PIT), are described to yield such fine and long-term stable emulsion adjuvants...
  2. doi request reprint Design and preclinical characterization of a novel vaccine adjuvant formulation consisting of a synthetic TLR4 agonist in a thermoreversible squalene emulsion
    Jean Haensler
    Sanofi Pasteur R and D, Marcy l Etoile, France Electronic address
    Int J Pharm 486:99-111. 2015
    ....
  3. doi request reprint [Introduction to novel vaccine adjuvants and their role in influenza vaccination]
    J Haensler
    Discovery R and D, Sanofi Pasteur, Campus Merieux, 1541, avenue Marcel Mérieux, 69280 Marcy l Etoile, France
    Ann Pharm Fr 71:104-8. 2013
    ..Nevertheless, the development of new adjuvants remains challenging in terms of quality and safety assurance and in terms of clinical and industrial development costs...